Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/9/2020
SIETES contiene 93091 citas

 
 
 1 a 20 de 484 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020:20 de julio. [Ref.ID 103690]
3. Cita con resumen
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough P, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, et al. for the mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med 2020:14 de julio. [Ref.ID 103684]
4. Cita con resumen
Samper E. ¿Podría la exposición a otros coronavirus protegernos frente al virus SARS-CoV-2?. eldiario.es 2020:16 de julio. [Ref.ID 103683]
6.Enlace a cita original Cita con resumen
Rathi S, Kumar P. Drug-induced liver injury — Types and phenotypes. N Engl J Med 2019;381:3 de octubre. [Ref.ID 103189]
9. Cita con resumen
Wadström H, Frisell T, Askling J, for the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice. A nationwide cohort study from Sweden. JAMA Intern Med 2017;177:1605-12. [Ref.ID 102143]
10. Cita con resumen
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86. [Ref.ID 102138]
11. Cita con resumen
Zost SJ, Parkhouse K, Gumina ME, Kim K, Díaz Pérez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains . Proceedings of the National Academy of Sciences of the United States of America 2017:6 de noviembre. [Ref.ID 102123]
12. Cita con resumen
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn G, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jacoki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun T-W. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med 2016:9 de noviembre. [Ref.ID 100922]
13. Cita con resumen
Chahal JS, Khan OF, Cooper CL, McPartlan JS, Tsosie JK, Tilley LD, Sidik SM, Lourido S, Langer R, Bavari S, Ploegh HL, Anderson DG. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proceedings of the National Academy of Sciences of the United States of America 2016;113:E4133-42. [Ref.ID 100595]
14. Cita con resumen
N.L.. Why gene-therapy drugs are so expensive. The Economist 2016:1. [Ref.ID 100562]
16.Tiene citas relacionadas Cita con resumen
Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention. an open-label, randomised controlled trial. Lancet 2015;386:2413-21. [Ref.ID 99767]
17.Tiene citas relacionadas
Maguire JH. Treatment of Chagas’ disease — Time is running out. N Engl J Med 2015;373:1369-70. [Ref.ID 99431]
18.Tiene citas relacionadas Cita con resumen
Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi Jr A, Rosas F, Villena E, Quiroz R, Bonilla R, Britto C, Guhl F, Velazquez E, Bonilla L, Meeks B, Rao-Melacini P, Pogue J, Mattos A, Lazdins J, Rassi A, Connolly SJ, Yusuf S, for the BENEFIT Investigators. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med 2015;373:1295-306. [Ref.ID 99430]
19. Cita con resumen
Villegas S. Enfermedad de Alzheimer: nuevas estrategias terapéuticas. Med Clin (Barc) 2015;145:76-83. [Ref.ID 99323]
20. Cita con resumen
Hatemi G, Melikoglu M, Tunc R, Korkmaz C, Ozturk BT, Mat C, Merkel PA, Calamia KT, Liu Z, Pineda L, Stevens RM, Yazici H. Apremilast for Behçet's syndrome - A phase 2, placebo-controlled study. N Engl J Med 2015;372:1510-8. [Ref.ID 99058]
Seleccionar todas
 
 1 a 20 de 484 siguiente >>